- Home
- DCOM vs COGT Comparison
DCOM vs COGT Comparison
Compare DCOM & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DCOM
- COGT
- Stock Information
- Founded
- DCOM 1864
- COGT 2014
- Country
- DCOM United States
- COGT United States
- Employees
- DCOM N/A
- COGT N/A
- Industry
- DCOM Major Banks
- COGT Biotechnology: Pharmaceutical Preparations
- Sector
- DCOM Finance
- COGT Health Care
- Exchange
- DCOM Nasdaq
- COGT Nasdaq
- Market Cap
- DCOM 1.2B
- COGT 1.1B
- IPO Year
- DCOM 1996
- COGT 2018
- Fundamental
- Price
- DCOM $30.48
- COGT $15.52
- Analyst Decision
- DCOM Buy
- COGT Strong Buy
- Analyst Count
- DCOM 2
- COGT 11
- Target Price
- DCOM $36.75
- COGT $21.20
- AVG Volume (30 Days)
- DCOM 194.1K
- COGT 2.1M
- Earning Date
- DCOM 10-24-2025
- COGT 11-11-2025
- Dividend Yield
- DCOM 3.29%
- COGT N/A
- EPS Growth
- DCOM N/A
- COGT N/A
- EPS
- DCOM 0.87
- COGT N/A
- Revenue
- DCOM $314,165,000.00
- COGT N/A
- Revenue This Year
- DCOM $49.66
- COGT N/A
- Revenue Next Year
- DCOM $16.29
- COGT N/A
- P/E Ratio
- DCOM $34.79
- COGT N/A
- Revenue Growth
- DCOM N/A
- COGT N/A
- 52 Week Low
- DCOM $23.25
- COGT $3.72
- 52 Week High
- DCOM $37.60
- COGT $16.22
- Technical
- Relative Strength Index (RSI)
- DCOM 54.53
- COGT 71.71
- Support Level
- DCOM $29.35
- COGT $13.72
- Resistance Level
- DCOM $31.23
- COGT $16.22
- Average True Range (ATR)
- DCOM 0.75
- COGT 0.69
- MACD
- DCOM -0.09
- COGT 0.24
- Stochastic Oscillator
- DCOM 46.36
- COGT 85.02
About DCOM Dime Community Bancshares Inc.
Dime Community Bancshares Inc operates as a holding company. It gathers deposits from customers within its market area and via the internet and invests them in multifamily residential, commercial real estate, commercial and industrial (C&I) loans, and one-to-four family residential real estate loans, as well as mortgage-backed securities, obligations of the U.S. government and government- sponsored enterprises (GSEs), and corporate debt and equity securities. The company has one reportable segment which is Community Banking.
About COGT Cogent Biosciences Inc.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.